Baird raised the firm’s price target on Caris Life Sciences (CAI) to $28 from $26 and keeps an Outperform rating on the shares. The firm updated its model following solid Q4 results and 2026 outlook ahead of expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target lowered to $35 from $40 at JPMorgan
- Caris Life Sciences price target lowered to $35 from $42 at Citi
- Caris Life Sciences reports Q4 EPS 28c, consensus 10c
- Caris Life Sciences sees 2026 revenue $1.0B-$1.02B, consensus $979.7M
- Caris Life Sciences initiated with an Outperform at Baird